Conduct CT in Indian population: CDSCO Panel Tells AstraZeneca for Anifrolumab
New Delhi: Highlighting that the there is no study data available in Indian population for monoclonal antibody Anifrolumab 150mg/ml concentrate for solution for infusion, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) has opined the drug major AstraZeneca that the firm should conduct clinical trial in Indian population.
This came after the firm presented the proposal to import and marketing of the drug Anifrolumab concentrate for solution for infusion 150 mg/ml indicated for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy with local clinical trial waiver.
Systemic lupus erythematosus (SLE), is the most common type of lupus. SLE is an autoimmune disease in which the immune system attacks its own tissues, causing widespread inflammation and tissue damage in the affected organs. It can affect the joints, skin, brain, lungs, kidneys, and blood vessels. There is no cure for lupus, but medical interventions and lifestyle changes can help control it.
Anifrolumab is a monoclonal antibody that inhibits type 1 interferon receptors, indicated in the treatment of moderate to severe systemic lupus erythematosus. Anifrolumab is a type 1 interferon receptor (IFNAR) inhibiting IgG1κ monoclonal antibody indicated in the treatment of adults with moderate to severe systemic lupus erythematosus.
The standard therapy for systemic lupus erythematosus consists of antimalarials like hydroxychloroquine, glucocorticoids like dexamethasone, and disease modifying antirheumatic drugs like methotrexate.
Anifrolumab is an immunoglobulin gamma 1 kappa (IgG1k) monoclonal antibody that selectively binds to subunit 1 of type 1 interferon receptor( INFAR1). This binding of anifrolumab to IFNAR1 halts the activity of the receptor, reducing downstream signalling and gene transcription of inflammatory mediators. Unlike other anti-type 1 interferon (IFN) agents that aim only to neutralize IFN alpha, anifrolumab antagonizes the receptor responsible for cellular signaling induced by IFN alpha, IFN beta, IFN epsilon, IFN kappa, and IFN omega.
At the recent SEC meeting for Analgesic & Rheumatology held on December 14th 2022, the expert panel reviewed the proposal presented by the drug major AstraZeneca to import and market the monoclonal antibody Anifrolumab 150mg/ml concentrate for solution for infusion which is used in the treatment of moderate to severe systemic lupus erythematous.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.